1 |
Binet J, A Auquier, ONE AUTHOR, et al (1981). A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer, 48, 198-206.
DOI
|
2 |
Byrd J C, S Stilgenbauer, ONE AUTHOR, et al (2004). Chronic lymphocytic leukemia. ASH Education Program Book, 2004, 163-83.
|
3 |
Crespo M, F Bosch, ONE AUTHOR, et al (2003). ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. New England J Med, 3488, 1764-75.
|
4 |
Dhodapkar M, A Tefferi, ONE AUTHOR, et al (1993). Prognostic features and survival in young adults with early/intermediate chronic lymphocytic leukemia (B-CLL): a single institution study. Leukemia: official journal of the Leukemia Society of America. Leukemia Res Fund, 7, 1232.
|
5 |
Di Giovanni S, G Valentini, ONE AUTHOR, et al (1989). Beta-2-microglobulin is a reliable tumor marker in chronic lymphocytic leukemia. Acta haematologica, 81, 181-5.
DOI
|
6 |
Dighiero G, T Hamblin (2008). Chronic lymphocytic leukaemia. The Lancet, 371, 1017-29.
DOI
|
7 |
Dighiero G, K Maloum, ONE AUTHOR, et al (1998). Chlorambucil in indolent chronic lymphocytic leukemia. New England J Med, 338, 1506-14.
DOI
ScienceOn
|
8 |
Doneda L, M Montillo, ONE AUTHOR, et al (2003). Interphase fluorescence in situ hybridization analysis of del (11)(q23) and del (17)(p13) in chronic lymphocytic leukemia: a study of 40 early-onset patients. Cancer genetics and cytogenetics, 140, 31-6.
DOI
|
9 |
Furman R R (2010). Prognostic markers and stratification of chronic lymphocytic leukemia. ASH Education Program Book, 2010, 77-81.
|
10 |
Glassman A B, K J Hayes (2005). The value of fluorescence in situ hybridization in the diagnosis and prognosis of chronic lymphocytic leukemia. Cancer genetics and cytogenetics, 158, 88-91.
DOI
|
11 |
Gordon L I, J Andersen, ONE AUTHOR, et al (1995). Advanced diffuse non-Hodgkin's lymphoma. Analysis of prognostic factors by the international index and by lactic dehydrogenase in an intergroup study. Cancer, 75, 865-73.
DOI
|
12 |
Hallek M, I Langenmayer, ONE AUTHOR, et al (1999). Elevated serum thymidine kinase levels identify a subgroup at high risk of disease progression in early, nonsmoldering chronic lymphocytic leukemia. Blood, 93, 1732-7.
|
13 |
Kay N, S O'brien, ONE AUTHOR, et al (2007). The role of prognostic factors in assessing 'high-risk'subgroups of patients with chronic lymphocytic leukemia. Leukemia, 21, 1885-91.
DOI
|
14 |
Krober A, T Seiler, ONE AUTHOR, et al (2002). mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood, 100, 1410-16.
|
15 |
Lai R, S O'Brien, ONE AUTHOR, et al (2002). Prognostic value of plasma interleukin-6 levels in patients with chronic lymphocytic leukemia. Cancer, 95, 1071-5.
DOI
|
16 |
Mainou-Fowler T, H M Dignum, ONE AUTHOR, et al (2004). The prognostic value of CD38 expression and its quantification in B cell chronic lymphocytic leukemia (B-CLL). Leukemia & lymphoma, 45, 455-62.
DOI
|
17 |
Molica S, A Alberti (1987). Prognostic value of the lymphocyte doubling time in chronic lymphocytic leukemia. Cancer, 60, 2712-6.
DOI
|
18 |
Montserrat E, F Gomis, ONE AUTHOR, et al (1991). Presenting features and prognosis of chronic lymphocytic leukemia in younger adults [see comments]. Blood, 78, 1545-51.
|
19 |
Molica S, D Levato, ONE AUTHOR, et al (1999). Clinicoprognostic implications of simultaneous increased serum levels of soluble CD23 and -microglobulin in B-cell chronic lymphocytic leukemia. Eur J Haematol, 62, 117-22.
|
20 |
Montserrat E (2002). Classical and new prognostic factors in chronic lymphocytic leukemia: where to now? The Hematology J, 3, 7-9.
DOI
|
21 |
Moreno C, E Montserrat (2010). Genetic lesions in chronic lymphocytic leukemia: what's ready for prime time use? Haematologica, 95, 12-5.
DOI
|
22 |
Mozaheb Z, A Aledavood, ONE AUTHOR, et al (2011). Distributions of major sub-types of lymphoid malignancies among adults in Mashhad, Iran. Cancer epidemiol, 35, 26-9.
DOI
|
23 |
Omoti C, O Awodu, ONE AUTHOR, et al (2007). Chronic lymphoid leukaemia: clinico-haematological correlation and outcome in a single institution in Niger Delta region of Nigeria. Int J Laboratory Hematol, 29, 426-32.
DOI
|
24 |
Oscier D G, A C Gardiner, ONE AUTHOR, et al (2002). Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors. Blood, 100, 1177-84.
|
25 |
Rai K R, A Sawitsky, ONE AUTHOR, et al (1975). Clinical staging of chronic lymphocytic leukemia. Blood, 46, 219-34.
|
26 |
Shanafelt T D, S M Geyer, ONE AUTHOR, et al (2004). Prognosis at diagnosis: integrating molecular biologic insights into clinical practice for patients with CLL. Blood, 103, 1202-10.
|
27 |
Ripolles L, M Ortega, ONE AUTHOR, et al (2006). Genetic abnormalities and clinical outcome in chronic lymphocytic leukemia. Cancer Genetics and Cytogenetics, 171, 57-64.
DOI
|
28 |
Rozman C, E Montserrat (1995). Chronic lymphocytic leukemia. New England J Med, 333, 1052-67.
DOI
ScienceOn
|